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Abstract
As anesthesia professionals practicing primarily in the intraoperative setting,
understanding genetic conditions contributing to surgical blood loss along with available
treatment regimens is paramount. As von Willebrand disease continues to be the most
recognized and common inherited coagulopathy, an advanced level of understanding of the
disease along with prophylactic measures and acute means to control intraoperative hemorrhage
is warranted. The purpose of this Independent Project is to provide a thorough and detailed
examination of von Willebrand disease along with treatment options both widely accepted in the
medical community and new, innovative advances. An expansive literature review was
performed through the University of North Dakota’s Harley E. French Library of Health
Sciences. The literature review provided information on all genetic variants and subtypes of von
Willebrand disease along with specific and detailed treatment plans for those undergoing surgical
procedures. Treatment modalities include the use of desmopressin, von Willebrand factor
concentrates, blood products such as cryoprecipitate, tranexamic acid, and estrogen derivatives.
Unfortunately, a curative medication is not available to von Willebrand disease patients. In order
to prevent catastrophic hemorrhagic complications, a familiarity of all treatment options
available to anesthesia professionals can provide the difference between an uneventful
intraoperative course and one with potentially disastrous implications.
Keywords: von Willebrand disease, anesthetic management, desmopressin, vWF
concentrate, cryoprecipitate
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Anesthetic Implications for Patients with von Willebrand Disease
First described in 1962 by a physician from Finland named Dr. Erik von Willebrand, von
Willebrand disease (vWD) continues to be the most common inherited bleeding disorder
prevalent in roughly 1 – 2% of the world’s population (Nagelhout & Plaus, 2014). The genetic
disease originated in the Baltic Sea specifically on a small island where multiple generations of
family members died from acute, spontaneous bleeding episodes with no signs of trauma or
gross injury. Initially termed pseudohemophilia due to the similarity in the clinical presentation,
aside from the obvious fact that this condition affected both males and females, vWD patients
were found to have extended or prolonged bleeding times in the absence of thrombocytopenia
(Pagon, Adam & Ardinger, 2014). Further advances in clinical identification and laboratory
testing continue to be investigated allowing for early diagnosis and treatment of potential
catastrophic bleeding complications secondary to vWD.
The perioperative period poses risks to patients with no medical history let alone those
with an advanced, inherited coagulation disorder such as vWD. As anesthesia providers, surgical
blood loss remains at the forefront of monitoring importance and therefore a knowledge and
understanding of inherited coagulation disorders is vital. A thorough appreciation of the
coagulation pathway is necessary to adequately understand treatment options for those with
bleeding diatheses, specifically those treatment options available to patients with vWD.
Furthermore, typical postoperative or intraoperative pain management techniques, such as spinal
or epidural anesthesia, are poorly understood by anesthesia practitioners when providing care to
vWD patients. Continuing education is necessary to provide proper care for those who provide
anesthesia to this patient population (Hara, Kishi & Sata, 2009).
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Multiple treatment options are available based on clinical subtype or variant of vWD and
anesthesia providers should at the very least be familiar with these medications and therapies.
Those medications are desmopressin or DDAVP, blood products such as cryoprecipitate, vWF
concentrates such as Haemate-P or Humate-P, tranexamic acid and aminocaproic acid (Neff &
Sidonio, 2014). Advances will continue to be made for this patient population and anesthesia
providers will need continuing education to adapt to an ever changing hematological landscape.
Case Report
The case being explored involves a 31 year old, 138 kg patient presenting for a robotic
hysterectomy for the removal of a malignant ovarian mass secondary to Cowden’s syndrome.
The patient was categorized as an ASA 3 with no known allergies. Past medical history included
hypertension, hyperlipidemia, anemia, colon and liver cancer, Cowden’s syndrome, von
Willebrand disease type 2A, depression, anxiety, gastroesophageal reflux disease and a noncorrected hiatal hernia. The patient reports no history of anesthetic complications. Surgical
history included a tonsillectomy and adenoidectomy, laparoscopic appendectomy, laparoscopic
cholecystectomy and a laparoscopic hemicolectomy. Current medication regimen included
lisinopril, citalopram and tramadol with patient admitting to non-compliance with her
medications. A thorough preoperative examination included vital signs which were as follows:
blood pressure 158/105, heart rate 88, respiratory rate 16, oxygen saturation 98%, and a
temperature of 98.1. Laboratory data included a complete blood cell count noting a hemoglobin
of 10.2 g/dl, hematocrit of 29 g/dl, platelet count of 180 per mm3 and a complete metabolic panel
that was within normal limits except for a potassium of 3.3 mEq/l and a creatinine of 1.3 mg/dL.
The patient’s coagulation studies demonstrated a PT/INR of 11.1 sec and 1.3 sec respectively
with no vWF levels or factor VIII levels documented. The patient was given 6900 IU of vWF
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concentrate 30 minutes prior to surgical incision because the patient had developed
tachyphylaxis secondary to multiple administrations of desmopressin.
A rapid sequence was chosen based on the patient’s history of reflux disease and hiatal
hernia. The patient presented with a Mallampati IV, short thryomental distance, limited neck
range of motion and previous documentation of difficult intubation with a grade 2/3 with a video
laryngoscope. Pre-oxygenation was performed for 10 minutes with adequate ramping and the
medications given were as follows: versed 2mg, fentanyl 150mcg, rocuronium 5mg, propofol
200mg, and succinylcholine 200mg. The patient’s airway was secured using a video
laryngoscope confirmed with the presence of an end tidal carbon dioxide wave form and
auscultated bilateral breath sounds. The 7.0 endotracheal tube was taped and secured while the
patient was placed on pressure control ventilation (PCV) with an inspiratory pressure of 22, rate
of 14, peak end expiratory pressure (PEEP) of 5 and tidal volume achieved was 520 – 560 mLs.
An orogastric tube was then placed to decompress the stomach to allow satisfactory visualization
of the surgical field.
Depth of anesthesia was maintained using Desflurane 7 – 8% with doses of fentanyl 2550 mcg, rocuronium 10 – 20 mg and 1 gram of Ofirmev given prior to surgical incision. The
patient was then placed in steep Trendelenburg position and the intraoperative course proceeded
uneventfully. Muscle relaxants were reversed with neostigmine 5mg and glycopyrrolate 0.8mg.
Anti-emetics were given which included Zofran 4mg and Decadron 5mg. A total of 2300 mLs
of intravenous fluid was infused, urine output was 200 mLs and total estimated blood loss was
150 mLs. An awake extubation was performed uneventfully in the operating room, patient was
placed on a non-rebreather at 10 liters per minute and once in the post anesthesia care unit
(PACU) the patient was placed on Bipap mask which was planned and not due to respiratory
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distress or hypercapnia. The patient reported being comfortable with a pain level of 2/10 and did
not report any post-operative nausea, vomiting or intraoperative awareness. Subsequently, the
patient was discharged from PACU and was discharged home 3 days later after a successful
hospital stay which include no adverse hemorrhagic events.
Discussion
von Willebrand Disease
The inherited coagulation disorder, vWD, is characterized by a malfunctioning clotting
factor called von Willebrand factor (vWF). The level to which factor is defective depends on the
variant or subtype of vWD either type 1, type 2A, type 2B, type 2M, type 2N or type 3 (Pagon,
Adam, & Ardinger, 2014). The role of vWF in the clotting cascade involves assisting in platelet
adhesion while working synergistically with plasma factor VIII (Nagelhout & Plaus 2014). The
vWF is a large glycoprotein located within and produced in plasma, platelets, endothelial cells
and megakaryocytes. When a tissue injury occurs, vWF attracts platelets to the site of the injury
to assist in the formation of a platelet plug, initiates the transport of factor VIII to form fibrin
clots and finally protects factor VIII from an internal degradation process known as in vivo
proteolysis (Mannucci et al., 2002). The mucocutaneous bleeding events in the vWD patients
are not only the result of defective vWF but also due to an abnormal communication between
vWF and glycoprotein Ib receptors (Federici, 2014). The inherited bleeding disorder may only be
discovered post-traumatic injury and has been known to increase in severity as a patient ages
(Pagon, Adam, & Ardinger, 2014).

VON WILLEBRAND DISEASE AND ANESTHESIA

8

vWD Subtypes/Variants
Classification of the specific variant of vWD allows advanced medical providers to
adequately treat, both prophylactically and acutely, in those patients with vWD of all subtypes.
The International Society on Thrombosis and Haemostasis (ISTH) proposed the classification of
vWD patients in 2010 and this continues to be the preferred classification method (Laffen et al.,
2014).
Type 1
The most commonly occurring form of vWD is the type 1 variant which occurs in 65% of
patients with vWD and tends to be heterogeneous in nature. A wide range of intrinsic vWF
levels are found to occur in this population with levels ranging from 5% to 40% depending on
specific patient pathology. Mutations of vWF are present in 65% to 70% of vWD type 1 patients
with the mutations being represented by missense substitutions, leaving 35% of vWD patients
with no mutations within intrinsic vWF. Studies in type 1 vWD patients focus on endothelial
cells, which produce vWF, to determine specific disease severity (James & Lillicrap, 2013).
Mucocutaneous bleeding is the primary manifestation in this variant of vWD (Pagon, Adam, &
Ardinger, 2014).
Type 2
The type 2 variant of vWD presents with four separate subtypes used to further classify
disease pathology. Type 2A patients represent 20% to 25% of those with vWD and appear to
have clinically lost platelet dependent functions. Laboratory values which indicate the type 2A
subtype include low vWF antigen and low vWF ristocetin cofactor activity. Comparatively,
missense and substitution mutations account for this subtype as well as the type 1 variant of
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vWD (James & Lillicrap, 2012). This patient population presents with either mild or moderate
bleeding in the mucocutaneous centers of the body (Pagon, Adam, & Ardinger, 2014).
The clinically significant difference between type 2B and the other type 2 variants is the
presence of accompanying thrombocytopenia. This unique clinical feature is the result of a
specific missense mutation present in only this subtype. Exclusively, this subtype seems to
drastically worsen during both pregnancy and stress which increases the mutant protein in the
circulating plasma. This results in platelet clumping further exacerbating bleeding risk (James &
Lillicrap, 2013). The clinical presentation in this subtype manifests as mild to moderate
mucocutaneous bleeding with the unique feature of thrombocytopenia (Pagon, Adam, &
Ardinger, 2014).
The type 2M variant of vWD is characterized by vWF mutations resulting in the loss of
function of glycoprotein Ib receptors as well as decreased collagen binding. Again, missense
mutations are the culprit for this specific vWD variant leading to its unique clinical presentation.
The classic laboratory test for type 2M vWD is the poor response to the administration of
desmopressin (James & Lillicrap, 2013). The clinical presentation is generally mild to moderate
mucocutaneous bleeding (Pagon, Adam, & Ardinger, 2014).
The type 2N variant results in a severe deficiency in intrinsic factor VIII levels and
generally presents in a genetically recessive fashion which is contrary to the genetically
dominant fashion of the other variants. Intrinsic factor VIII levels in this population are 5% to
40% of normal (Lillicrap, 2013). Clinical presentation includes the potential for catastrophic and
fatal bleeding episodes which tend to follow patterns seen with hemophilia A (Pagon, Adam, &
Ardinger, 2014).
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Type 3
The most severe subtype of vWD has been identified as type 3. Intrinsic levels of vWF
are often less than 5% or even undetectable in specific patients. Mutations of vWF for this
subtype involve both missense and deletion pathology which prevents the production of intrinsic
factor VIII (Lillicrap, 2013). Clinical manifestations in this subtype include excessive bleeding
such as musculoskeletal bleeding episodes leading to potential permanent immobility (Pagon,
Adam, & Ardinger, 2014).
Clinical Presentation
Clinical manifestations in vWD patients vary greatly and depend highly on the specific
variant or subtyped identified via extensive laboratory testing. As previously stated, this data can
assist practitioners with both diagnosis and treatment. Specific coagulopathy can manifest with
bleeding in the mucocutaneous areas of the body or delayed hemostasis post injury or surgical
incision (Federici, 2014). One of the most commonly reported symptoms in the female patient is
menorrhagia since menarche with males also likely to present with genitourinary bleeding.
Other clinical manifestations include bruising of an unknown origin, prolonged or recurrent
epistaxis, bleeding following routine or daily dental maintenance or examinations,
gastrointestinal bleeding and hypovolemia related hypotension from blood loss due to childbirth
(Pagon, Adam, & Ardinger, 2014). Unfortunately, this coagulation disorder may not be
recognized until a traumatic event because the disease can be silent with little warning of its
existence (Auerswald & Kreuz, 2008).
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Demographics
The inherited genetic coagulation disorder vWD tends to affect females at a greater
frequency than males, roughly 2:1 in recent demographic studies. However, this data has been
questioned by multiple researchers due to the diseases appearance during the onset of female
menses. No geographic or ethnic population has been identified to be at greater risk for
inheriting vWD (Lillicrap, 2013). The majority of patients afflicted with vWD in the United
States are Caucasian, roughly 75% according to the Centers for Disease Control. On a global
scale, racial distribution appears to be 65% Caucasian, 28% African American and the rest
represented by people of Middle East, Far East and Native American decent (Flood et al., 2011).
Laboratory Analysis
In general, an overreaching and expansive approach is used when trying to determine the
nature and severity of an individual’s coagulopathy and vWD is not exempt from this detection
strategy. Detailed laboratory analysis is part of the three main criteria used to diagnose vWD
which includes the following: a bleeding history since childhood, reduced vWF activity in the
plasma and lastly a genetically identified bleeding history encompassing more than two
generations in a lineage (Federici, 2014).
Complete blood cell (CBC) analysis is typically normal with some vWD patients
presenting with microcytic anemia or in the case of vWD type 2B, thrombocytopenia can occur
concurrently with other analyses suggesting vWD. Activated partial thromboplastin time (aPTT)
is also generally within normal limits, however when severe deficiency in factor VIII is
observed, as is the case with type 3 vWD, aPTT can be prolonged. Other general laboratory tests
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used include skin bleeding times and platelet function assays but these tests will not be able to
identify vWD from other disorders of coagulation (Pagon, Adam, & Ardinger, 2014).
Fortunately, a more specific hematological analysis is available when vWD is suspected
from general analysis or clinical presentation and includes specific hematology assays. A
ristocetin cofactor assay (vWF:RCo.) specifically measures the functional ability of vWF and its
ability to cohere to platelets with a normal range being 50 – 200 IU/dL. The quantity of vWF
protein or antigen (vWF:Ag.) directly measures plasma levels of the antigen with a normal range
of 50 – 200 IU/dL. Finally, the activity of factor VIII in the clotting cascade can directly be
measured by factor VIII:C levels with a normal range identified to be between 50 – 150 IU/dL
(Pagon, Adam, & Ardinger, 2014).
The previously mentioned laboratory analysis is specific for the diagnosis of vWD but
does not provide specific information on the variant or subtype. If any of the hemostasis factor
assays result in abnormal values, specific subtypes and vWD variants can be identified with the
following tests: vWF multimer analysis, ristocetin-induced platelet agglutination, binding of
factor VIII by vWF, and collagen binding assay. The vWF multimer analysis identifies vWF
oligomers in blood plasma which is useful in identifying specifically vWD type 2A or 2B but can
be helpful identifying all type 2 vWD variants. The ristocetin-induced platelet agglutination
identifies the ability of vWF to attract platelets in the presence of the antibiotic ristocetin and an
abnormal result is typically indicative of vWD type 2B. The only test available to identify vWD
type 2N is to individually test the binding capacity factor VIII has in the presence of vWF. Type
3 vWD is diagnosed by exclusion criteria along with vWF levels less than 5% of normal.
Finally, the collagen binding assay is a test which measures the ability of vWF to connect to

VON WILLEBRAND DISEASE AND ANESTHESIA

13

collagen particles and is beneficial when determining patients with either type 1 or type 2 vWD
variants of all subtypes (Pagon, Adam, & Ardinger, 2014).
Genetic Testing
When detailed laboratory analysis combined with physical examination and history yields
a diagnosis of vWD, genetic testing is recommended in first degree relatives either with or
without a history of spontaneous or uncontrollable bleeding. Ideally, the International Society on
Thrombosis and Haemostasis (ISTH) recommends genetic testing on predisposed individuals
prior to onset of uncontrollable bleeding to identify either type or variant of vWD. Also, the
ISTH does not recommend laboratory testing until the patient is a minimum of 6 months of age.
Patients with type 3 vWD are recommended to undergo phenotypic analysis prior to attempts to
conceive children as the pregnancy and risk for hemorrhage pose a serious risk to both mother
and child (Laffen et al., 2014). According to Dr. David Lillicrap (2014), “given the severe
phenotype of type 3 vWD, genetic prenatal diagnosis of this variant provides results for families
and their physicians to make informed decisions about family planning and obstetric
management issues.” Seemingly as the severity, either identified by subtype or clinical
presentation, increases so too does the necessity for genetic testing and subsequent family
planning.
Treatment
For those affected by an acute bleeding episode secondary to an underlying pathology of
vWD or those looking for prophylaxis prior to surgery, many options are available of varying
efficacies. Identifying the individuals subtype and variant of vWD is of the utmost importance in
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determining the proper treatment method designed to achieve hemostasis. Typically, treatment
options are considered either non-concentrate or concentrate containing therapies.
Desmopressin
First opined to be a treatment option for vWD in 1977, desmopressin or DDAVP is a
derivative of the human body’s anti-diuretic hormone or ADH. Desmopressin has the ability to
raise intrinsic levels of vWF through agonistic activity on V2 vasopressin receptors. This
agonistic activity signals endothelial cells to increase production and release of both vWF and
factor VIII thereby raising intrinsic levels by as much as 2 to 3 times normal. However, clinical
results vary which is thought to be the result of short acting multimers. Initially, these multimers
achieve hemostasis but severe bleeding may re-occur following administration (Neff & Sidonio,
2014).
Clinicians generally recommend a test dose to determine an individual’s response to
desmopressin with subsequent doses to follow if hemostasis is achieved. In order to assess
patient responsiveness to desmopressin, intrinsic levels of vWF can be measured at 60 minutes
and 4 hours post administration. Desmopressin can be useful in treating vWD subtypes 1, 2A,
2M and 2N but is not recommended in type 2B related to the potential for worsening
thrombocytopenia post-administration. Also, desmopressin is not effective in type 3 vWD as
these patients produce less than 5% of normal vWF from endothelial cells. Desmopressin is
approved for the following routes of administration: intravenous, subcutaneous and intranasal
(Laffen et al., 2014).
Even though the response of desmopressin can be unreliable, DDAVP continues to be
used both prophylactically and acutely for dental procedures, minor surgeries and child birth.
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Standard dosing regimens include an intravenous dose or subcutaneous dose of 0.3mcg/kg given
over 30 minutes with an intranasal dosage recommendation of 150 mcg to 300 mcg. Side effects
reported include flushing, hypotension, hypertension, nausea, headache, hyponatremia, volume
overload, seizures and tachyphylaxis (Neff & Sidonio, 2014). Since desmopressin is a derivative
of the anti-diuretic hormone, the potential fluid volume overload and accompanying
hypertension can be mitigated by limiting fluid intake in the 24 hours post administration period
to an amount of 1 liter or less. Serial sodium levels should also be noted, particularly in children
under the age of 2 or if multiple doses of desmopressin are administered to persons of any age
(James & Goodeve, 2011).
Estrogen Derivatives
Typically reserved for women of childbearing age, oral contraceptives increase intrinsic
production of vWF from endothelial cells. Along with increasing vWF production and release,
the control of menstrual bleeding is also of benefit to the patient with vWD. However, as is the
case with most therapies, estrogen derivatives are not useful in the treatment of type 3 vWD or
the acute management of bleeding episode (Neff & Sidonio, 2014).
vWF concentrations
Fortunately, for patients with severe forms of vWD such as type 2N and type 3, there are
treatments available to raise intrinsic vWF levels. These medications are specifically
advantageous if major hemorrhage occurs or to be used on a prophylactic basis prior to surgery.
Currently there are multiple vWF concentrates being manufactured and operate under the trade
names Alphanate, Humate-P, Haemate-P and Wilate. These medications contain both vWF and
factor VIII which, as previously stated, work synergistically to form a platelet plug in the clotting
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cascade. However, each therapy contains a different ratio of vWF to factor VIII and are
designed to be used in specific situations either prophylactically or to achieve hemostasis during
acute bleeding episodes (Neff & Sidonio, 2014).
Treatment with vWF concentrate is the gold standard of care for the 20% – 30% of
patients who do not respond to desmopressin or do not produce intrinsic factor VIII. A
prospective study was performed by Mannucci and associates (2002) over 5 years involving 87
patients with vWD undergoing treatment either prophylactically or for the treatment of an acute
hemorrhage. This was the first study involving vWD patients and their response to vWF
concentrate. Skin bleeding times were the laboratory test of choice for the researchers along
with factor VIII assays. Patients of all subtypes and variants were tested in this study including
15 type 1 patients, 29 type 2A patients, 5 type 2B patients, and 32 type 3 patients along with both
genders being represented. The researchers observed and treated 87 acute bleeding episodes
with vWF concentrate, generally needing only a single bolus dose to achieve hemostasis, the
exception being type 3 vWD patients who have little to no intrinsic factor VIII. The dose given
for acute hemorrhagic episodes was 40 IU/kg with common bleeding sites being within the
gastrointestinal/genitourinary systems or within the nasal cavity. Ultimately, all acute bleeds
achieved hemostasis with the use of vWF concentrates. The research team also used vWF
concentrate for surgical prophylaxis in 71 patients over the 5 year study. Initial surgical
prophylaxis dose was 60 IU/kg followed by subsequent 40 IU/kg doses if bleeding persisted.
Success of vWF was measured via actual blood loss versus expected blood loss based on
procedure and in all cases the actual blood loss was less than the documented expected value.
The vWF concentrate demonstrated both safety and efficacy as only mild side effects were

VON WILLEBRAND DISEASE AND ANESTHESIA

17

reported with no major complications secondary to the infusions. Blood loss was adequately
controlled in all subjects (Mannucci et al., 2002).
A systematic review was performed by Dr. Erik Berntorp at Malmo University Hospital
in Sweden and found to produce similar results. Looking at data from patients non-responsive to
desmopressin, Dr. Berntorp found 90% of patients had corrected bleeding times with doses of
vWF concentrate. Further research allowed Dr. Berntorp (2009) and his research team to
conclude, vWF “effectively reduced the risk of bleeding complications in vWD patients
undergoing elective surgery” (p. S14). This systematic analysis further reinforces the efficacy of
vWF concentrate (Berntorp, 2009).
To reinforce the data further, exploration involving vWF concentrate dosing was studied
by Auerswald and Kreuz (2009). Based on the findings, the researchers recommended dosages
based on bleeding severity and concluded: for major bleeding and trauma a loading dose of 40 –
60 IU/kg be given intravenously followed by a maintenance dose of 40 – 50 IU/kg for 3 days
keeping vWF levels greater than 50% and for minor bleeding events a dose of 40 – 50 IU/kg be
given intravenously for either 1 or 2 doses depending on individual response (Auerswald &
Kreuz, 2009).
As previously stated, the medication appears to be extremely safe with minimal side
effects reported. Initially, viral complications were considered, but no viral infection pathology
has been noted in the literature. Other complications include: anaphylactic type reactions,
transient hyperthermia, vWF inhibitory antibodies, hemolysis, thromboembolic complications
and hypervolemia. Thromboembolic events represent less than 1% of reported side effects
(Berntorp, 2009).
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Tranexamic acid
Tranexamic acid is an anti-fibrinolytic agent which opposes the disintegration of
thrombus formation. A lysine derivative, tranexamic acid prevents plasmin from binding with
fibrin thus inhibiting the breakdown of a previously made platelet plug or blood clot. This
therapy is typically adjunctive with desmopressin and has been approved for dental procedures
and minor surgery. Available routes of administration include local infiltrations, mouthwash,
oral and intravenous (Neff & Sidonio, 2014). Tranexamic acid is specifically useful in oral
surgery and dental procedures to combat the natural proteolytic enzymes present in the oral
cavity (Federici et al., 2000). General dosing guidelines recommend 650mg orally prior to
surgery for prophylaxis or 1300 mg every 8 hours for 5 days for females using it with the
occurrence of menstruation. Intravenous dosing for tranexamic acid generally involves 10mg/kg
over 15 minutes (Neff & Sidonio, 2014).
Cryoprecipitate
Cryoprecipitate is a plasma derived blood product containing vWF, factor I, VIII, XIII,
and fibrinogen (Nagelhout & Plaus, 2014). Generalized use is falling out of favor related to the
presence of acute viral pathology post-infusion. The use of cryoprecipitate is reserved for when
vWF concentrates are unavailable. Each unit of cryoprecipitate contains toughly 80 – 100 units
of factor VIII (Neff & Sidonio, 2014).
Anesthetic Considerations
One of the primary duties of the anesthesia professional is optimizing the patient’s status
intraoperatively by understanding basic and advanced methods of controlling surgical blood loss.
The anesthetist must adapt a plan of care for each individual with vWD and tailor that plan based
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on the proposed surgical intervention both major and minor, elective or emergent. Anesthetic
considerations will be presented for multiple patient populations including obstetrics, pediatrics,
dental prophylaxis, regional anesthesia and the trauma patient.
Obstetric Considerations
The benefits of neuraxial anesthesia in the obstetric population include a decreased or
eliminated need for opioids and related side effects for mother and baby, faster recovery time,
decreased mortality, decreased surgical blood loss and improved patient satisfaction (Choi &
Brull, 2009). However, deciding to perform spinal or epidural anesthesia in the vWD patient
poses inherent risks and theoretically can lead to dangerous and even fatal complications.
Fortunately, pregnant vWD patients tend to exhibit a remission of symptoms and inherent vWF
levels increase with the peak occurring during the third trimester (Butwick & Carvalho, 2007).
Choi and Brull (2009) performed a case review involving 10 research studies with 74 vWD
undergoing spinal/epidural anesthesia for labor analgesia and found no complications reported.
All subtypes were represented including 71 type 1, 2 type 2, and 1 type 3 vWD patient. The
patients’ vWF levels were drawn prior to initiating spinal or epidural anesthesia and all levels
were within normal limits with the exception of 10 patients. Patients with abnormal vWF were
treated with either desmopressin or synthetic vWF concentrates and regional anesthesia
proceeded without complications (Choi & Brull, 2009).
Spinal hematoma secondary to spinal or epidural anesthesia is an extremely rare
complication but must be considered in the patient with vWD or other inherent bleeding
disorders. The risk of spinal hematoma is 1 in 200,000 or 0.0005% even in the presence of
inherited coagulopathy. Spinal or epidural anesthesia is considered to be safe in the vWD patient
if based on coagulation studies especially inherent vWF levels. Careful monitoring of vWF must
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be performed to ensure patient safety and each patient should have a unique plan of care
developed (Butwick & Carvalho, 2007). A desmopressin challenge test, which involves a
loading dose of desmopressin and subsequent aPTT and factor VIII levels being drawn, can be
performed to further assist the provider in determining the safety and efficacy of the regional
anesthetic technique (Cata et al., 2009). In the presence of vWD, postpartum hemorrhage risk is
nullified if inherent vWF and factor VIII levels are 30 – 40 % of normal which is typical in the
third trimester even in the most severe forms of vWD. Other techniques to minimize risk for
spinal hematoma include removing the epidural catheter immediately in the postpartum period.
After delivery of baby, the vWD patient’s inherent factor VIII and vWF levels will begin to
decrease, thus hastening the necessity to remove the epidural catheter (Butwick & Carvalho,
2007).
Spinal and epidural anesthesia in the vWD patient poses unique risks that must be
understood by the anesthetist providing labor analgesia. However, in the presence of vWF levels
within normal limits, the use of these regional anesthetic techniques appears safe and efficacious.
If vWF levels are not normalized, the use of spinal or epidural anesthesia can proceed following
the administration of either desmopressin or vWF concentrate if vWF levels are normalized post
treatment. If levels have not normalized, neuraxial anesthesia should be deferred. Each labor
and delivery plan for the vWD patient must take bleeding risk into account and the patient and
provider can optimize the labor and delivery plan based on this information.
Pediatric Considerations
Specialized and individualized care must be provided for the pediatric vWD disease
patient. Generally, advanced manifestations of vWD are not seen until teenage years related to
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inherent vWF levels being increased in the neonate similar to the obstetric population (James &
Goodeve, 2011).
Preoperative surgical recommendations for the pediatric patient undergoing various
procedures include the consultation of a hematologist specializing in the pediatric population
(Berlucchi et al., 2002). The most common symptoms observed in the pediatric population with
von Willebrand disease are easy bruising and bleeding within the oral cavity (Witmer et al.,
2009). Coagulation tests performed focus primarily on inherent vWF and factor VIII levels. If
the patient is greater than 2 years of age, a loading dose of desmopressin 0.3mcg/kg is
recommended 30 – 45 minutes prior to surgical incision to control bleeding and maintain
hemostasis in types 1 and specific variants of type 2 as previously discussed (Berlucchi et al.,
2002). Determinants observed to predict post-operative bleeding in the pediatric vWD patients
include inherent vWF levels, desmopressin trial response, age, and estimated blood loss of the
initial surgery. Synthetic factor VIII can also be administered and as extensively covered
previously, there are minimal safety concerns with this medication. Typically, hesitation of
administering factor VIII results from monetary concerns (Witmer et al., 2009). During the
immediate postoperative period, serial serum sodium levels should be drawn to assess for
hyponatremia resulting from fluid overload. Hyponatremia can manifest as intractable seizures
which, if not identified and promptly treated, can be fatal. The pediatric patient should be
admitted at a minimum of overnight and closely observed for hemorrhage both external and
internal. Other recommendations to control postoperative hemorrhage include oral tranexamic
acid for 7 to 10 days (Berlucchi et al., 2002). Aminocaproic acid can be a useful antifibrinolytic
agent as it prevents the degradation and lysis of clot formation, but does not contribute to the
initial maintenance of hemostasis (Witmer et al., 2009). The patient should be evaluated by the
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surgeon weekly for 1 month and then routine follow up with the pediatric hematologist to
monitor vWF and factor VIII levels (Berlucchi et al., 2002).
With roughly 400,000 adenotonsillar procedures performed annually in the United States,
it is one of the most common cases performed in the pediatric population. The relative risk of
post-operative hemorrhage in the healthy pediatric population is 1.5% to 5% and drastically
increased in the patient with vWD. As extensive laboratory testing is generally not performed in
the pediatric patient, vWD can potentially be discovered in the postoperative period if
unexpected or continual hemorrhaging persists after surgical intervention. Further complicating
matters for the pediatric vWD patient, proteolytic enzymes proliferate the saliva making
achieving hemostasis challenging (Witmer et al., 2009).
In a comprehensive study involving pediatric patients with vWD, Witmer and associates
(2009) studied 41 cases of adenotonsillar surgery. Preoperative surgical interventions included a
0.3mcg/kg dose of desmopressin 30 minutes prior to incision and aminocaproic acid was
initiated the night prior to surgery and continued for 5 days. Of the 41 pediatrics studied, 38
required subsequent re-dosing of desmopressin to control tonsillar hemorrhage. Postoperative
hemorrhage requiring further surgical intervention was reported in 7 out of the 41 patients with 5
of those patients requiring immediate surgical intervention. Transfusion of packed red blood
cells was reported in 2 patients with an average hemoglobin decrease of 4.8 g/dl in these patients.
Based on this expansive study, postoperative hemorrhage in the vWD pediatric patient
undergoing adenotonsillar procedures is roughly 17% to 44% accounting for a high risk surgical
procedure. Witmer and associates (2002) recommend adenotonsillar type procedures in the
pediatric vWD patient only be performed as a last resort intervention for acute tonsillitis or
obstructive sleep apnea with multiple, documented apneic periods. Furthermore,
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recommendations were made to avoid aminocaproic acid in this patient population as nausea is a
common side effect and acute vomiting appeared to be a contributing factor to postoperative
hemorrhage. In the pediatric patient with known vWD, the use of vWF concentrates and
laboratory analysis of inherent vWF levels and factor VIII levels is recommended to optimize
surgical condition (Witmer et al., 2009).
Regional Anesthesia
As with the obstetric patient population, many similarities exist in the management of
regional anesthesia techniques in the non-obstetric patient with vWD. The choice of whether to
proceed with regional anesthesia in the vWD patient primarily focuses on laboratory results
particularly inherent vWF and factor VIII levels. Other analysis can include vWF antigen levels,
APTT, PT/INR, platelets, and the consultation of a hematologist or oncologist. An inherent vWF
level greater than 50% is preferred but hemorrhagic complications from regional anesthesia
techniques is considered to be minimal if inherent vWF levels are greater than 30%. The risk of
acute hemorrhage, particularly spinal hematoma, drastically increases when inherent vWF levels
are less than 10% (Stedford & Pittman, 2000).
The advantages of neuraxial anesthetic practices in the non-obstetric patient can be highly
beneficial over general anesthesia and include increased postoperative pain control, decrease
gastrointestinal complications, improved and hastened rehabilitation, and diminished surgical
mortality. Pharmacological intervention prior to regional anesthesia must heavily focus on
inherent vWF levels and treat according to subtype or variant of vWD. Either desmopressin or
vWF concentrates are the preferred pre-treatment prior to regional anesthesia and associated
interventions. If epidural catheters are placed, removal of the catheter is recommended as soon
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as clinically possible to prevent bleeding diathesis from occurring or worsening if already
present (Choi & Brull, 2009).
Generally, peripheral nerve blocks are safer and preferred in contrast with neuraxial
anesthesia with indwelling catheter placement in the vWD patient. However, epidurals when
used for postoperative pain management, allow the surgeon and multidisciplinary team to avoid
anti-platelet drugs commonly used to treat pain such as non-steroidal anti-inflammatory drugs
and aspirin. Researchers Hara, Kishi, and Sata (2009) recommend vWF levels be greater than
50% but prefer vWF levels to be 100% or greater with maintenance of previously stated levels
for the length of time the catheter is in place. Furthermore, the aforementioned research team
provided guidelines for the ability of the anesthesia professional to place epidural/spinal
catheters which include: the patient has a documented positive response to desmopressin, a
loading dose of desmopressin 0.3mcg/kg is given 30 – 45 minutes prior to catheter placement
and a thorough and documented consent is obtained by the anesthesia professional. The prompt
removal of the catheter is necessary with 24 hour observation post removal to assess the vWD
patient for severe and potentially catastrophic complications especially epidural or spinal
hematoma. Therefore, under specific circumstances with documented laboratory analysis,
regional anesthesia can be an option for anesthetic management in the patient with vWD (Hara,
Kishi, & Sata, 2009).
Dental Considerations
As one of the most common manifestations of vWD is bleeding in the oral cavity, dental
procedures can provide challenges to healthcare professionals to maintain hemostasis. As
previously stated, proteolytic enzymes proliferate in the saliva making the oral cavity a likely
place for acute hemorrhage especially during dental procedures ranging from routine tooth
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cleanings to comprehensive extractions related to dental caries. The most difficult location
within the oral cavity to control bleeding is within the tongue, mandible and lip. The preferred
clinical intervention used to treat bleeding in this location is oral tranexamic acid using a “swash
and spit” method. Bleeding within the gingival tissue surrounding the individual tooth is
generally controlled with direct pressure applied to the area. Other interventions, generally
performed by the dental professional, include packing, splinting and the use of oxidized cellulose
to assist in clot formation (Morimoto et al., 2005).
Interventions used prior to dental procedures are similar to those discussed for surgical
procedures in previous sections. However, a few unique caveats exist when dealing with
procedures involving the oral cavity. According to Morimoto and associates (2005), tranexamic
acid is recommended prior to all dental procedures due to the antifibrinolytic activity and also
the ability of tranexamic acid to oppose the lysis of clots within the oral cavity. These distinct
mechanisms of action make tranexamic acid a vital and crucial medication for controlling
intraoral bleeding in vWD patients (Morimoto et al., 2005). Another potential intervention to
control oral bleeding is the use of fibrin glue to synergistically work with tranexamic acid to
achieve hemostasis (Federici et al., 2000). Further recommendations proposed by Morimoto and
associates (2005) include the following parameters based on subtype of vWD and include: 0.3 –
0.4 mcg/kg of desmopressin for patients with type 1 and 2A vWD undergoing surgical dental
extractions with a total of three doses given intravenously, for vWD not responsive to
desmopressin and all other types of vWD undergoing surgical dental extractions a minimum of
two doses of vWF concentrate should be given intravenously and repeated four to six times as
needed, and finally for routine extractions simple pressure applied to the gingival area should be
adequate to achieve hemostasis.

VON WILLEBRAND DISEASE AND ANESTHESIA

26

Researchers at the Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre and
Department of Internal Medicine sought to determine the effects of local versus systemic
methods to treat dental hemorrhage post intervention. A total of 64 participants were involved in
the study spanning a 4 year period. The local interventions used were a combination of
tranexamic acid and fibrin glue with the systemic interventions comprising either desmopressin
or vWF concentrate. All surgical interventions were performed by the same surgeon and
consisted of dental extractions and periodontal surgery. Of the 64 vWD patient participants, 32
received local therapy and 32 received systemic interventions. Systemic interventions of
desmopressin and vWF concentrate were discussed at length in previous sections and doses were
identical in this study. The researchers found no significant difference in outcomes based on the
type of therapy received. Each group had one reported bleeding episode and both were treated
with fibrin glue to achieve local hemostasis. The researchers concluded that a combination of
tranexamic acid and fibrin glue was equally effective as desmopressin and vWF concentrate for
controlling mucosal bleeding in vWD patients undergoing oral or periodontal surgery. The
researchers also highlighted the significant cost reduction when using local therapy to achieve
and maintain hemostasis (Federici et al, 2000).
Trauma
The trauma patient presents multiple challenges in hemostasis and this can be further
complicated when a patient, unbeknownst to the healthcare professional, has a bleeding diathesis
such as vWD. Severe complications are likely in the trauma patient and likelihood of fatality is
drastically increased if the patient has vWD. Interventions the patient can perform to assist
healthcare providers in treatment would be to wear an identification bracelet noting the presence
of vWD and ideally detailing the specific subtype. This information can allow for a unique
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treatment plan which can hasten hemostasis and prevent death. One of the most important
interventions hematologists can execute is a thorough and detailed education on the potential
severity of the disease. Seemingly innocent blunt trauma can prove fatal if not identified
promptly which is why every patient with vWD must investigate any sign of internal bleeding
(Slam et al., 2008).
Trauma patients with uncontrollable hemorrhage either internal or external are candidates
for massive transfusions protocols. Patients with vWD require interventions, however, that are
more specific to the disease and replacing inherent factors that are not present in the vWD
patient. Slam and associates (2009) have developed a transfusion protocol for trauma patients
with vWD that includes the following parameters placed in order of intervention: desmopressin
0.3mg/kg intravenously over 30 minutes, if head injury present or major trauma give 50 IU/kg of
vWF concentrate intravenously, if either joint, soft tissue or muscle hemorrhage present give 25
IU/kg of vWF concentrate intravenously, if oral mucosa bleeding present give 50 IU/kg vWF
concentrate intravenously with aminocaproic acid orally and finally cryoprecipitate can be added
as a last resort (Slam et al., 2008). Treatment for victims of trauma with vWD present unique
complications to healthcare and anesthesia providers alike and unfortunately carry a high risk of
mortality. Treatment options are available, however knowledge or identification of the patient’s
condition must be recognized early to ensure highest chance for survival.
Case Study
In retrospect, the aforementioned case scenario was adequately managed and confirmed
by the available literature presented in the Independent Project. The 6900 IU dose of vWF
concentrate sufficiently controlled and maintained intraoperative hemostasis based on actual
versus expected blood loss. As stated in the literature, the medication was both safe and
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efficacious which is why it continues to by the gold standard treatment for vWD patients.
Unfortunately, patients are not usually identified by the variant of vWD leaving providers in a
potentially difficult position. Typically, patients are categorized by severity of symptoms and
not subtype as advanced laboratory analysis can be cost prohibitive. Furthermore, patients are
characterized as being either responsive to desmopressin or non-responsive to desmopressin. For
patients who are not responsive to desmopressin, as was the scenario in the aforementioned case
study, vWF concentrate therapy is the preferred treatment of choice. Further analysis of
laboratory methods should be ascertained to streamline costs associated with identifying the
subtype of vWD to assist medical and anesthesia providers in treatment modalities. Again, the
case presented was adequately managed and the patient had a desirable outcome postoperatively.
Conclusion
Patients with vWD pose unique risks during the intraoperative period and treatment
information specific to each individual must be understood by the anesthesia professional. The
research and literature reviewed documented approved treatment options for each subtype of
vWD along with the various safety and efficacy of each intervention. Within the realm of
anesthesia, certain interventions, such as regional anesthetic techniques like spinal and epidural
anesthesia, may pose an increased bleeding risk for patients with vWD leading to potential
hemorrhagic complications. The management of various patient populations with vWD such as
obstetrics and pediatrics each carry inherent risks which make the practice of anesthesia difficult.
The treatment options focus on two mainstays and include desmopressin and vWF concentrates.
Each of these medications have characteristics of benefit to the vWD patient. The overarching
treatment continues to be vWF concentrates and is effective at treating all subtypes of vWD.
Genetic testing continues to make phenomenal strides allowing for more accurate treatment plans
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tailored to treat each individual vWD patient. The information provided within this Independent
Project will allow anesthesia professionals to be familiar with the underlying pathology of vWD
and, along with the current treatment recommendations, provide the vWD patient with the safest
and most efficacious intraoperative experience possible.

VON WILLEBRAND DISEASE AND ANESTHESIA

30

References
Auerswald, G. & Kreuz, W. (2008). Haemate P/Humate-P for the treatment of von Willebrand
disease: Considerations for use and clinical experience. Haemophilia, 14, 39-46.
Berlucchi, M., Tomenzoli, D., Nicolai, P., & Lusk, R.P. (2002). Adenotonsillectomy in children
with von Willebrand disease: How and when. A case report with review of the literature.
International Journal of Pediatric Otorhinolaryngology, 65, 253 – 256.
Berntorp, E. (2009). Haemate P/Humate-P: A systematic review. Thrombosis Research, 124(1),
S11-S14.
Butwick, A.J., & Carvalho, B. (2007). Neuraxial anesthesia for cesarean delivery in a parturient
with type 1 von Willebrand disease and scoliosis. Journal of Clinical Anesthesia, 19, 230
– 233.
Cata, J.P., Hanna, A., Tetzlaff, J.E., Bishai, A., & Barsoum, S. (2009). Spinal anesthesia for a
cesarean delivery in a woman with type-2M von Willebrand disease: Case report and
mini-review. International Journal of Obstetric Anesthesia, 18, 276 – 279.
Choi, S., & Brull, R. (2009). Neuraxial techniques in obstetric and non-obstetric patients with
common bleeding disorders. Regional Anesthesia, 109(2), 648 – 660.
Federici, A.B. (2014). Clinical and laboratory diagnosis of VWD. Hematology 524 – 530.
Federici, A.B., Sacco, R., Stabile, F., Carpendo, M., Zingaro, E., & Mannucci, P.M. (2000).
Optimising local therapy during oral surgery in patient with von Willebrand disease:
Effective results from a retrospective analysis of 63 cases. Haemophilia, 6, 71 – 77.

VON WILLEBRAND DISEASE AND ANESTHESIA

31

Flood, V.H., Gill, J.C., Friedman, K.D., Bellissimo, D.B., Haberichter, S.L., & Montgomery,
R.R. (2011). von Willebrand disease in the United States: A perspective from Wisconsin.
Semin Thromb Hemost., 37(5). doi:10.1055/s-0031-1281039.
Hara, K., Kishi, N., & Sata, T. (2009). Considerations for epidural anesthesia in a patient with
type 1 von Willebrand disease. Journal of Anesthesia, 23, 597 – 600.
doi:10.1007/s00540-009-0782-z
James, P.D., & Goodeve, A.C. (2011). von Willebrand disease. Genet Med., 13(5).
doi:10.1097/GIM.0b013e3182035931.
James, P.D., & Lillicrap, D. (2012). von Willebrand disease: Clinical and laboratory lessons
learned from the large von Willebrand disease studies. American Journal of Hematology,
87(01, 4-11. doi:10.1002?ajh.23142
Laffan, M.A., Lester, W., O’Donnell, J.S., Will, A., Tait, R.C., …Keeling, D.M. (2014). The
diagnosis and management of von Willebrand disease: A United Kingdom haemophilia
centre doctors organization guideline approved by the British committee for standards in
haematology. British Journal of Haematology, 167(4), 453-465. doi:10.1111/bjh.13064
Lillicrap, D. (2013). von Willebrand disease: Advances in pathogenetic understanding,
diagnosis, and therapy. Blood, 122(23), 3735-3740. doi:10.1182/blood-2013-06-498303
Mannucci, P.M., Chediak, J., Hanna, W., Byrnes, J., Ledford, M., Ewenstein, B.M., … &
Kessler, C. (2002) Treatment of von Willebrand disease with a high-purity factor
VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood, 99(2),
450 – 456.

VON WILLEBRAND DISEASE AND ANESTHESIA
Morimoto, Y., Yoshioka, A., Sugimoto, M., Imai, Y., & Kirita, T. (2005). Haemostatic
management of intraoral bleeding in patients with von Willebrand disease. Oral
Diseases, 11, 243 – 248.
Nagelhout, J. J., & Plaus, K.L. (2014). Nurse anesthesia (5th ed.). St. Louis, Missouri: Elsevier
Saunders.
Neff, A.T., & Sidonio, R.F. (2014). Management of VWD. Hematology, 536-541.
Pagon, R.A., Adam, M.P., & Ardinger, H.H. GeneReviews. Seattle (WA): University of
Washington, Seattle; 1993-2016.
Slam, K., Zyromski, N., Nowicki, P., Serrano, P., & Purtill, M.A. (2008). Common bleeding
disorders: A potential catastrophe for the trauma victim. Recommendations for the
treatment of von Willebrand’s disease. The Journal of Trauma, Injury, Infection, and
Critical Care, 64(5), 1373 – 1375.
Stedford, J.C., & Pittman, J.A.L. (2000). Von Willebrand disease and neuraxial anesthesia.
Anaesthesia, 55, 1213 – 1235.
Witmer, C.M., Elden, L., Butler, R.B., Manno, C.S., & Raffini, L.J. (2009). Incidence of
bleeding complications in pediatric patients with type 1 von Willebrand disease
undergoing adenotonsillar procedures. The Journal of Pediatrics, 155(1), 68 – 72.

32

VON WILLEBRAND DISEASE AND ANESTHESIA
Appendix
The following PowerPoint presentation was presented at the spring North Dakota
Association of Nurse Anesthetists meeting in Fargo, North Dakota on April 15th, 2016.
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